Article

Investor day reveals Carl Zeiss Meditec AG's plans

Jena, Germany-During a presentation at Carl Zeiss Meditec AG's Investor Day in Munich, managers of the Strategic Business Units (SBUs) Surgical Ophthalmology, Ophthalmic Systems, and Neuro/ENT Surgery outlined their departments' strategies and challenges.

Jena, Germany-During a presentation at Carl Zeiss Meditec AG's Investor Day in Munich, managers of the Strategic Business Units (SBUs) Surgical Ophthalmology, Ophthalmic Systems, and Neuro/ENT Surgery outlined their departments' strategies and challenges.

The company also gave an overview of new products including the high-definition device system (Cirrus HD-OCT), operation microscope, (OPMI Pentero), and femtosecond laser (VisuMax), which was demonstrated during an eye exam to correct vision defects.

The company's IOL portfolio also was presented, which now covers the entire spectrum in the area of IOLs and ranges from simple, monofocal lenses for the treatment of cataracts to technically demanding multifocal and microincision lenses for refractive surgery.

"Overall, our goal was to give participants a better insight into our positioning as an integrated medical technology company," said Ulrich Krauss, chief executive officer and president of Carl Zeiss Meditec AG. "We wanted to present our individual growth drivers in the SBUs Surgical Ophthalmology, Ophthalmological Systems, and Neuro/ENT Surgery in a clear and tangible way. The discussion this prompted following the presentations showed us that this mission was successfully accomplished."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.